Article Details
Retrieved on: 2024-06-04 22:56:36
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Tagrisso (osimertinib; AstraZeneca) reduced the risk of disease progression or death by 84% in patients with unresectable, stage III epidermal growth ...
Article found on: www.appliedclinicaltrialsonline.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here